Article info
Original research
Pharmaceutical industry sponsorship of academic conferences: ethics of conflict of interest
- Correspondence to Professor Saroj Jayasinghe, Department of Medical Humanities, Faculty of Medicine, Colombo 00800, Sri Lanka; saroj{at}clinmed.cmb.ac.lk
Citation
Pharmaceutical industry sponsorship of academic conferences: ethics of conflict of interest
Publication history
- Received March 21, 2020
- Revised May 23, 2020
- Accepted May 31, 2020
- First published July 23, 2020.
Online issue publication
November 29, 2021
Article Versions
- Previous version (23 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Biomedical conflicts of interest: a defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy
- ‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders
- Proliferation of gynaecological scientific societies and their financial transparency: an Italian survey
- Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites
- Managing conflicts of interest and commitment: academic medicine and the physician's progress
- Sponsorship of national and regional professional paediatrics associations by companies that make breast-milk substitutes: evidence from a review of official websites
- Conflict of interest among Italian medical oncologists: a national survey
- Moving towards less biased research
- World Medical Association reviews doctors' links with drug companies
- Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement